Evidence map›Paper›PMID 37141143›Full record

ReviewRadiation research2023

The Future of Radioactive Medicine.

M Sproull, E Wilson, R W Miller, K Camphausen

Open access · greenAbstract readReview
In one paragraph

Review in Radiation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

M SproullRadiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
E WilsonRadiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
R W MillerRadiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
K CamphausenRadiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
National Cancer Institute · US

Funding

The Synergy Between Radiotherapy and Molecularly Targeted AgentsZIASC010373 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$22.2M
Clinical Radiation Physics ServiceZIDSC006329 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MILLER, ROBERT · 2009 to 2025
$6.0M
The Synergy Between Radiotherapy and Molecularly Targeted AgentsZ01SC010373 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI CAMPHAUSEN, KEVIN A · 2001 to 2008
$1.8M
Intramural NIH HHS Z01 SC010373Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA SC010373
6 · The paper itself

Abstract

The discovery of X rays in the late 19th century heralded the beginning of a new age in medicine, and the advent of channeling the power of radiation to diagnose and treat human disease. Radiation has been leveraged in medicine in a multitude of ways and is a critical element of cancer care including screening, diagnosis, surveillance, and interventional treatments. Modern radiotherapy techniques include a multitude of methodologies utilizing both externally and internally delivered radiation from a variety of approaches. This review provides a comprehensive overview of contemporary radiotherapy methodologies, the field of radiopharmaceuticals and theranostics, effects of low dose radiation and highlights the phenomena of fear of exposure to radiation and its impact in modern medicine.

Indexed as

Radiation OncologyHumansPrecision MedicineRadiographyX-Rays

Identifiers

PMID37141143
PMCPMC10466314
OpenAlexW4368359939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.